WASHINGTON — There were no Martin Shkreli moments.

Instead, Tuesday’s congressional hearing on high drug prices served mostly as a retreading of arguments that lawmakers and the drug industry have spent years fine-tuning.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It’s not the FDA that stops patients from purchasing direct as you call it. States require medications to be dispensed by prescription from a licensed pharmacy. Pharmaceutical companies have and do own pharmacies (mail order or specialty). However, the payers/PBMs refuse to put the pharmacy in their network so patients with insurance coverage can’t access.

  • I watched what could be called a “Dog and Pony” Show. The most important set of culprits were not there. PBMs and Insurance companies who create the formularies. One has to pay to be on the formulary. Higher price ($100.00 per pill) from company “A” @ 20% rebate pays higher absolute dollar $20.00 rebate to PBM1 vs. lower price from company B ($80.00 per pill) @ 20% rebate pays $16.00. PBM will include company A on the formulary. Middleman wins and patient who cares in a mutually subsidized system.

    If patient can buy directly from the pharma companies and no middleman, we will or should see prices drop. However, Ms/r. FDA would prevent this to happen.

    If anything meaningful happens in the next 600 DAYS it would be a MIRACLE.

    Life will go on.

    • It’s not the FDA that stops patients from purchasing direct as you call it. States require medications to be dispensed by prescription from a licensed pharmacy. Pharmaceutical companies have and do own pharmacies (mail order or specialty). However, the payers/PBMs refuse to put the pharmacy in their network so patients with insurance coverage can’t access.

Your daily dose of news in health and medicine

Privacy Policy